Condition: Acute Myeloid Leukemia · Stem Cell Transplantation · Sponsor: Marker Therapeutics, Inc.
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10\^6 cells (flat dosing).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| City of Hope National Medical Center | Duarte, California, United States | — |
| Moores Cancer Center at University of Californa San Diego | La Jolla, California, United States | — |
| UCLA Department of Medicine | Los Angeles, California, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| Mayo Clinical Cancer Center-Florida | Jacksonville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | — |
| University of Chicago | Chicago, Illinois, United States | — |
| University of Iowa Hospitals & Clinics | Iowa City, Iowa, United States | — |
| Mayo Clinic Cancer Center-Rochester | Rochester, Minnesota, United States | — |
| John Theurer Cancer Center at Hackensack UMC | Hackensack, New Jersey, United States | — |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04511130